Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Wykoff, Charles CCharles CWykoffAbreu, FrancisFrancisAbreuAdamis, Anthony PAnthony PAdamisBasu, KarenKarenBasuEichenbaum, David ADavid AEichenbaumHaskova, ZdenkaZdenkaHaskovaLin, HughHughLinLoewenstein, AnatAnatLoewensteinMohan, ShaunShaunMohanPearce, Ian AIan APearceSakamoto, TaijiTaijiSakamotoSchlottmann, Patricio GPatricio GSchlottmannSilverman, DavidDavidSilvermanSun, Jennifer KJennifer KSunWells, John AJohn AWellsWillis, Jeffrey RJeffrey RWillisTadayoni, RaminRaminTadayoniCHANG-HAO YANG et al.2024-01-182024-01-182022-02-1901406736https://scholars.lib.ntu.edu.tw/handle/123456789/638610To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial growth factor-A bispecific antibody.enEfficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsjournal article10.1016/S0140-6736(22)00018-6350855032-s2.0-85124662878https://api.elsevier.com/content/abstract/scopus_id/85124662878